The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Dimethyldithiocarbamate results in increased expression of HMOX1 protein Trientine inhibits the reaction [Dimethyldithiocarbamate results in increased expression of HMOX1 protein]
cupric chloride promotes the reaction [Dimethyldithiocarbamate results in decreased activity of and results in decreased ubiquitination of UBA1 protein]; Dimethyldithiocarbamate results in decreased activity of and results in decreased ubiquitination of UBA1 protein; Trientine inhibits the reaction [Dimethyldithiocarbamate results in decreased activity of and results in decreased ubiquitination of UBA1 protein]; zinc chloride promotes the reaction [Dimethyldithiocarbamate results in decreased activity of and results in decreased ubiquitination of UBA1 protein]
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of AKT1 protein; [alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of AKT1 protein
mancozeb inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; mancozeb inhibits the reaction [Metribolone binds to and results in increased activity of AR protein] mancozeb results in decreased activity of AR protein
mancozeb results in increased expression of BAX mRNA; mancozeb results in increased expression of BAX protein lupeol inhibits the reaction [mancozeb results in increased expression of BAX mRNA]
mancozeb results in decreased expression of BCL2 mRNA; mancozeb results in decreased expression of BCL2 protein lupeol inhibits the reaction [mancozeb results in decreased expression of BCL2 mRNA] alpha-Tocopherol inhibits the reaction [mancozeb results in decreased expression of BCL2 protein]
mancozeb results in increased activity of CASP3 protein Acetylcysteine inhibits the reaction [mancozeb results in increased cleavage of CASP3 protein] mancozeb results in increased cleavage of and results in increased activity of CASP3 protein
Acetylcysteine inhibits the reaction [mancozeb results in decreased activity of CAT protein]; lupeol inhibits the reaction [mancozeb results in decreased activity of CAT protein]; Quercetin inhibits the reaction [mancozeb results in decreased activity of CAT protein] Colforsin inhibits the reaction [mancozeb results in decreased activity of CAT protein]
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of CCND1 protein mancozeb results in increased expression of CCND1 protein
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of GSK3B protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [mancozeb results in increased activity of MAPK1 protein]; mancozeb results in increased localization of and results in increased activity of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [mancozeb results in increased activity of MAPK3 protein]; mancozeb results in increased localization of and results in increased activity of MAPK3 protein
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of MYC protein mancozeb results in increased expression of MYC protein mancozeb results in decreased expression of MYC protein alpha-Tocopherol inhibits the reaction [mancozeb results in decreased expression of MYC protein]
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of PTK2B protein modified form
mancozeb results in increased phosphorylation of RELA protein mancozeb affects the localization of RELA protein Acetylcysteine inhibits the reaction [mancozeb affects the localization of RELA protein]; lupeol inhibits the reaction [mancozeb affects the localization of RELA protein]; mancozeb inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of RELA protein] mancozeb results in increased localization of RELA protein
mancozeb affects the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of TNF protein] mancozeb inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; mancozeb inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; mancozeb inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of TNF protein]
mancozeb results in decreased expression of TRP53 mRNA; mancozeb results in decreased expression of TRP53 protein mancozeb results in increased expression of TP53 mRNA lupeol inhibits the reaction [mancozeb results in increased expression of TP53 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA]
Maneb results in decreased expression of ACHE protein [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of ACHE mRNA
[Maneb co-treated with Paraquat] results in increased expression of AIF1 protein; [Paraquat co-treated with Maneb] results in increased expression of AIF1 protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of AIF1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of AIF1 protein]
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of AKT1 protein; [alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of AKT1 protein; [Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA]
Maneb results in decreased activity of ALDH5A1 protein [Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of ATP5A1 protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP5A1 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP5A1 protein]
[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA] [Paraquat co-treated with Maneb] results in increased expression of BAK1 protein; Maneb inhibits the reaction [BAK1 protein affects the susceptibility to Paraquat]; Paraquat inhibits the reaction [BAK1 protein affects the susceptibility to Maneb] Maneb results in increased expression of BAK1 mRNA; Maneb results in increased expression of BAK1 protein
[Paraquat co-treated with Maneb] results in increased expression of BAX protein; BAX protein affects the susceptibility to [Paraquat co-treated with Maneb] Maneb results in increased expression of BAX protein [Maneb co-treated with Paraquat] results in increased expression of BAX mRNA; [Paraquat co-treated with Maneb] results in increased expression of BAX protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BAX protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BAX protein]
[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA] Maneb results in increased expression of BCL2 mRNA; Maneb results in increased expression of BCL2 protein
[Maneb co-treated with Paraquat] results in decreased expression of BDNF mRNA [Paraquat co-treated with Maneb] results in decreased expression of BDNF mRNA; [Paraquat co-treated with Maneb] results in decreased expression of BDNF protein
Maneb results in increased expression of BIK mRNA; Maneb results in increased expression of BIK protein [Paraquat co-treated with Maneb] results in increased expression of BIK protein
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA
[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA; [Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA; [Paraquat co-treated with Maneb] results in increased expression of CASP9 protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP9 protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP9 protein] Maneb results in increased activity of CASP9 protein
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of CCND1 protein [Maneb co-treated with Paraquat] results in decreased expression of CCND1 mRNA
[Paraquat co-treated with Maneb] results in increased expression of CD68 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CD68 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA; LRRK2 protein mutant form inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]; SNCA protein inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of CDKN1A mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDKN1A mRNA]
[Paraquat co-treated with Maneb] results in increased phosphorylation of CHUK protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of CHUK protein]
[Maneb co-treated with Paraquat] results in decreased expression of CLCA1 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CLCA1 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]
[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA]
[Paraquat co-treated with Maneb] results in decreased expression of CPLX1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of CPLX1 protein
[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA] [Paraquat co-treated with Maneb] results in decreased expression of CREB1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 protein; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 protein modified form
[Paraquat co-treated with Maneb] results in increased expression of CSF1R mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CSF1R mRNA]
[Paraquat co-treated with Maneb] results in increased expression of CSF2RA mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CSF2RA mRNA]
[Maneb co-treated with Paraquat] results in increased expression of CTSL mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CTSL mRNA]
[Paraquat co-treated with Maneb] results in increased expression of NOX2 mRNA; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX2 mRNA]; diphenyleneiodonium inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX2 mRNA] [Paraquat co-treated with Maneb] results in increased expression of CYBB protein; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB protein]
Maneb results in increased activity of CYP1A1 protein Maneb results in decreased expression of CYP1A1 mRNA Maneb results in increased expression of CYP1A1 mRNA; Maneb results in increased expression of CYP1A1 protein
[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein; [Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein]; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA]
Maneb results in decreased activity of CYP2E1 protein Maneb results in increased expression of CYP2E1 mRNA; Maneb results in increased expression of CYP2E1 protein [Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein; [Maneb co-treated with Paraquat] results in increased expression of CYP2E1 mRNA; Acetylcysteine inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein]; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Acetylcysteine inhibits the reaction [Maneb results in increased expression of and results in increased activity of CYP2E1 protein]; Acetylcysteine inhibits the reaction [Maneb results in increased expression of CYP2E1 mRNA]; Maneb results in increased expression of and results in increased activity of CYP2E1 protein; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of and results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [Maneb results in increased expression of CYP2E1 mRNA] Maneb results in increased activity of CYP2E1 protein [Maneb co-treated with Paraquat] results in increased expression of CYP2E1 mRNA; [Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein; [Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of DAP3 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DAP3 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of DLST protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DLST protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DLST protein]
[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of EIF4G2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EIF4G2 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of ELK1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ELK1 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of ENO1 protein; [Paraquat co-treated with Maneb] results in decreased expression of ENO1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of ENO1 protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ENO1 protein]
[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA]
[Maneb co-treated with Paraquat] results in increased expression of FGFR3 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FGFR3 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of FOS mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FOS mRNA] [Paraquat co-treated with Maneb] results in decreased expression of FOS mRNA; [Paraquat co-treated with Maneb] results in decreased expression of FOS protein
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of GCLC mRNA Maneb results in increased activity of GCLC protein
[Paraquat co-treated with Maneb] results in increased expression of GFAP protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of GFAP protein]
[Paraquat co-treated with Maneb] results in decreased expression of GMFB mRNA; [Paraquat co-treated with Maneb] results in decreased expression of GMFB protein
GPX1 protein results in decreased susceptibility to [Paraquat co-treated with Maneb] [Maneb co-treated with Paraquat] results in increased expression of GPX1 mRNA Maneb results in decreased expression of GPX1 mRNA
Maneb results in increased expression of GPX4 mRNA [Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein [Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein]; NFE2L2 gene mutant form inhibits the reaction [Maneb results in increased expression of GPX4 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of GSK3B protein
[Acetylcysteine co-treated with Paraquat co-treated with Maneb] results in increased activity of GSR protein; [Silymarin co-treated with Maneb] results in increased activity of GSR protein; [Silymarin co-treated with Paraquat co-treated with Maneb] results in increased activity of GSR protein [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of GSR protein
[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein; [Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA; Acetylcysteine promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein]; Acetylcysteine promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA]; Acetylcysteine promotes the reaction [Maneb results in increased expression of and results in increased activity of GSTA4 protein]; Acetylcysteine promotes the reaction [Maneb results in increased expression of GSTA4 mRNA]; Maneb results in increased expression of and results in increased activity of GSTA4 protein; Silymarin promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein]; Silymarin promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA]; Silymarin promotes the reaction [Maneb results in increased expression of and results in increased activity of GSTA4 protein]; Silymarin promotes the reaction [Maneb results in increased expression of GSTA4 mRNA] Maneb results in increased activity of GSTA4 protein Maneb results in increased expression of GSTA4 mRNA; Maneb results in increased expression of GSTA4 protein
[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA]
Maneb results in increased expression of HMOX1 protein [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of HMOX1 protein
[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of HSP90AA1 mRNA; [Paraquat co-treated with Maneb] results in increased expression of HSP90AA1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSP90AA1 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of HSPA1B mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSPA1B mRNA]
[Paraquat co-treated with Maneb] results in increased expression of ICAM1 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ICAM1 mRNA]
[Paraquat co-treated with Maneb] results in increased expression of ICAM2 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ICAM2 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein]
[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA]
[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of IL1B mRNA] [Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA; [Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA; [Paraquat co-treated with Maneb] results in increased expression of IL1B protein; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA]; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]
[Paraquat co-treated with Maneb] results in increased expression of IL6 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL6 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of IRS2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IRS2 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of ITGAM protein; [Paraquat co-treated with Maneb] results in increased expression of ITGAM mRNA; [Paraquat co-treated with Maneb] results in increased expression of ITGAM protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ITGAM protein]; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ITGAM protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ITGAM mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of ITPR1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ITPR1 mRNA]
[Paraquat co-treated with Maneb] results in decreased expression of JUN mRNA; [Paraquat co-treated with Maneb] results in decreased expression of JUN protein
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of ACHE mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5R1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5RAP1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CHRM2 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of EFNB1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of FEZ1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEY2 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NDP mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NRG1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX6 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of POU3F3 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA; LRRK2 protein mutant form inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA]
[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK1 protein [Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK1 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK1 protein]
[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK3 protein [Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK3 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK3 protein]
[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA]
[Paraquat co-treated with Maneb] results in decreased expression of MBD3 mRNA; [Paraquat co-treated with Maneb] results in increased expression of MBD3 mRNA
[Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased metabolism of MEF2C protein; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased metabolism of MEF2C protein
[Paraquat co-treated with Maneb] results in increased expression of MTOR protein; Maneb promotes the reaction [Paraquat results in increased expression of MTOR protein]; Paraquat promotes the reaction [Maneb results in increased expression of MTOR protein]
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of MYC protein
[Maneb co-treated with Paraquat] affects the localization of NCF1 protein; [Paraquat co-treated with Maneb] results in increased expression of NCF1 protein; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NCF1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] affects the localization of NCF1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NCF1 protein]
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of GCLC mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of PRDX1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXN1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXNRD1 mRNA; Maneb results in increased expression of NFE2L2 protein NFE2L2 gene mutant form results in increased susceptibility to Maneb [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased abundance of Glutathione; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of GSR protein; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of HMOX1 protein; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in increased abundance of Manganese; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in increased abundance of Thiobarbituric Acid Reactive Substances; NFE2L2 gene mutant form inhibits the reaction [Maneb results in increased expression of GPX4 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA]
[Maneb co-treated with Paraquat] results in increased phosphorylation of and results in decreased expression of NFKBIA protein; [Paraquat co-treated with Maneb] results in increased degradation of and results in increased phosphorylation of NFKBIA protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased phosphorylation of and results in decreased expression of NFKBIA protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased degradation of and results in increased phosphorylation of NFKBIA protein]
[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; [Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA; [Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA; [Paraquat co-treated with Maneb] results in increased expression of NOS2 protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Genistein inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; pimagedine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; prolinedithiocarbamate inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA] [Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of NOS2 mRNA]
[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA]; diphenyleneiodonium inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA]
[Paraquat co-treated with Maneb] results in decreased expression of NR4A2 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of NR4A2 protein
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA; [Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA
[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of OAZ2 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of OAZ2 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of P2RY4 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of P2RY4 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of PCDH7 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PCDH7 mRNA]
3-bromo-7-nitroindazole inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of PCNA protein]; [Paraquat co-treated with Maneb] results in decreased expression of PCNA protein
[Maneb co-treated with Paraquat] results in decreased expression of PDE1B mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PDE1B mRNA]
[Maneb co-treated with Paraquat] results in increased expression of PDGFRA mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PDGFRA mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of PDHA1 mRNA; [Maneb co-treated with Paraquat] results in increased expression of PDHA1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PDHA1 protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PDHA1 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of PEBP1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PEBP1 protein]
[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein]
[Paraquat co-treated with Maneb] results in decreased expression of PRKACA mRNA; [Paraquat co-treated with Maneb] results in decreased expression of PRKACA protein
3-bromo-7-nitroindazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased nitrosation of PRKN protein]; [Paraquat co-treated with Maneb] results in increased expression of PRKN protein; [Paraquat co-treated with Maneb] results in increased nitrosation of PRKN protein
[Maneb co-treated with Paraquat] results in increased expression of PSEN1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PSEN1 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of PSMC4 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PSMC4 mRNA] [Paraquat co-treated with Maneb] results in decreased expression of PSMC4 mRNA
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of PTK2B protein modified form
[Maneb co-treated with Paraquat] results in decreased expression of RAF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of RAF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of RAF1 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of RB1 mRNA; Acetylcysteine inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of RB1 mRNA]; Acetylcysteine inhibits the reaction [Maneb results in increased expression of RB1 mRNA]
[Maneb co-treated with Paraquat] results in increased phosphorylation of RELA protein; [Paraquat co-treated with Maneb] results in increased phosphorylation of RELA protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased phosphorylation of RELA protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of RELA protein]
[Maneb co-treated with Paraquat] results in increased expression of RIPK1 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of RIPK1 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of RPL19 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of RPL19 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of SCAMP2 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SCAMP2 mRNA]
[Paraquat co-treated with Maneb] results in decreased expression of SLC18A2 mRNA; Ketoconazole inhibits the reaction [Maneb results in decreased expression of SLC18A2 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of SLC18A2 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of SLC18A2 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of SLC22A2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SLC22A2 mRNA]
[Paraquat co-treated with Maneb] results in decreased expression of SLC40A1 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of SLC40A1 protein]
[Paraquat co-treated with Maneb] results in decreased expression of SLC6A3 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of SLC6A3 protein SLC6A3 gene polymorphism affects the susceptibility to Maneb
[Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]; [Paraquat co-treated with Maneb] results in increased expression of SNCA protein; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ADORA1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of APBB1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ASCL1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP2 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DLL1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD2 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD5 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEYL mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX5 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of SEMA4D mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of SNCA protein]; SNCA protein inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]] SNCA gene mutant form results in increased susceptibility to Maneb [Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased abundance of Nitric Oxide; [Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased metabolism of MEF2C protein; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased abundance of Nitric Oxide; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased metabolism of MEF2C protein; Maneb promotes the reaction [Paraquat results in increased expression of SNCA protein]; Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]; Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]; SNCA protein mutant form results in increased susceptibility to [Paraquat co-treated with Maneb]; SNCA protein results in increased susceptibility to [Maneb co-treated with Paraquat]
SOD1 protein results in decreased susceptibility to [Paraquat co-treated with Maneb] [Maneb co-treated with Paraquat] results in increased expression of SOD1 mRNA [Paraquat co-treated with Maneb] results in decreased expression of SOD1 mRNA
[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein] Maneb results in decreased expression of SOD2 mRNA
[Maneb co-treated with Paraquat] results in decreased expression of STAT3 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT3 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT3 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of STAT4 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT4 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT4 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein]
[Maneb co-treated with Paraquat] results in decreased expression of SYT5 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SYT5 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SYT5 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of TGFB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TGFB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TGFB1 mRNA]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; [Paraquat co-treated with Maneb] results in decreased expression of TH protein; [Paraquat co-treated with Maneb] results in increased expression of TH protein; Genistein inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; Ketoconazole inhibits the reaction [Maneb results in decreased expression of TH protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TH protein]; pimagedine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; prolinedithiocarbamate inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TH protein] [Paraquat co-treated with Maneb] results in decreased expression of TH; [Paraquat co-treated with Maneb] results in decreased expression of TH mRNA; [Paraquat co-treated with Maneb] results in decreased expression of TH protein
Maneb results in increased expression of TNF mRNA [Maneb co-treated with Paraquat] results in increased expression of TNF mRNA; [Paraquat co-treated with Maneb] results in increased expression of TNF mRNA; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA] [Paraquat co-treated with Maneb] results in increased expression of TNF mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of TNF mRNA]
[Maneb co-treated with Paraquat] results in increased expression of TNFAIP3 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNFAIP3 mRNA]
3-bromo-7-nitroindazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TRP53 protein]; [Maneb co-treated with Paraquat] results in increased expression of TRP53 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of TRP53 protein; [Paraquat co-treated with Maneb] results in increased activity of TRP53 protein modified form; [Paraquat co-treated with Maneb] results in increased expression of TRP53 protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TRP53 mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TRP53 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of TRP53 protein modified form]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TRP53 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TRP53 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of TRP53 protein modified form]
[Maneb co-treated with Paraquat] results in increased expression of TRAF6 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TRAF6 mRNA]
[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein]
[Maneb co-treated with Paraquat] results in decreased expression of TUBB5 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of TUBB5 mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of UBB mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of UBB mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of UBB mRNA]
[Maneb co-treated with Paraquat] results in decreased expression of UCHL1 protein; [Paraquat co-treated with Maneb] results in decreased expression of UCHL1 mRNA
[Maneb co-treated with Paraquat] results in increased expression of UQCRC1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of UQCRC1 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of UQCRC1 protein]
[Maneb co-treated with Paraquat] results in decreased expression of VAMP5 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of VAMP5 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of VAMP5 mRNA]
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA
[Maneb co-treated with Paraquat] results in decreased expression of VPS45 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of VPS45 mRNA]
[Paraquat co-treated with Maneb] results in decreased expression of WNT1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of WNT1 protein
[Paraquat co-treated with Maneb] results in increased expression of WNT5A mRNA; [Paraquat co-treated with Maneb] results in increased expression of WNT5A protein
Dithiothreitol inhibits the reaction [Thiram results in decreased activity of HSD11B2 protein]; Ethylmaleimide promotes the reaction [Thiram results in decreased activity of HSD11B2 protein]; Thiram inhibits the reaction [HSD11B2 protein results in increased oxidation of Dexamethasone]
[2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in increased expression of LEP protein
[2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in decreased expression of LEPR mRNA
[2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in decreased expression of NMB mRNA
[2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in increased expression of NMBR mRNA
[2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in increased expression of NPY1R mRNA
Dithiothreitol inhibits the reaction [Thiram inhibits the reaction [Dexamethasone binds to NR3C1 protein]]; Thiram inhibits the reaction [Dexamethasone binds to NR3C1 protein]; Thiram inhibits the reaction [Hydrocortisone binds to NR3C1 protein]
Thiram results in increased expression of TNF mRNA Thiram inhibits the reaction [TNF protein results in decreased expression of PECAM1 protein]; Thiram inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; Thiram promotes the reaction [TNF protein results in increased expression of ICAM1 protein]
Zineb inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; Zineb inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
Zineb inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Zineb promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of ABCC2 mRNA
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of ABCC3 mRNA
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of ACOX1 mRNA
Ziram results in decreased expression of AMH mRNA; Ziram results in decreased expression of AMH protein Ziram results in increased expression of AMH mRNA
Acetylcysteine inhibits the reaction [Ziram results in decreased expression of and results in increased degradation of CASP1 protein]; Dithiothreitol inhibits the reaction [Ziram results in decreased expression of and results in increased degradation of CASP1 protein]; Edetic Acid inhibits the reaction [Ziram results in decreased expression of and results in increased degradation of CASP1 protein]; Mercaptoethanol inhibits the reaction [Ziram results in decreased expression of and results in increased degradation of CASP1 protein]; Ziram results in decreased expression of and results in increased degradation of CASP1 protein
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CD36 mRNA Ziram results in decreased expression of CD36 mRNA; Ziram results in decreased expression of CD36 protein
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CPT1A mRNA
Ziram results in decreased activity of CYP11A1 protein Ziram affects the expression of CYP11A1 mRNA; Ziram affects the expression of CYP11A1 protein Ziram results in decreased expression of CYP11A1 mRNA; Ziram results in decreased expression of CYP11A1 protein
Ziram results in decreased expression of CYP17A1 mRNA; Ziram results in decreased expression of CYP17A1 protein Ziram affects the expression of CYP17A1 mRNA; Ziram affects the expression of CYP17A1 protein Ziram results in decreased activity of CYP17A1 protein
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2B10 mRNA; [Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CYP2B10 mRNA
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2B9 mRNA
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of CYP2C55 mRNA
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of CYP2C29 mRNA
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of DIO1 mRNA
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of ECI1 mRNA
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of GFAP protein
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of HMGCS2 mRNA
Trientine inhibits the reaction [Ziram results in increased expression of HMOX1 protein] Ziram results in increased expression of HMOX1 mRNA; Ziram results in increased expression of HMOX1 protein
Ziram inhibits the reaction [[HSD11B1 protein results in increased reduction of 11-dehydrocorticosterone] which results in increased chemical synthesis of Corticosterone]; Ziram inhibits the reaction [HSD11B1 protein results in increased oxidation of NADP]; Ziram inhibits the reaction [HSD11B1 protein results in increased reduction of 11-dehydrocorticosterone] Ziram results in decreased expression of HSD11B1 mRNA; Ziram results in decreased expression of HSD11B1 protein Ziram results in decreased activity of HSD11B1 protein
Dithiothreitol inhibits the reaction [Ziram results in decreased activity of HSD11B2 protein]; Ziram inhibits the reaction [[HSD11B2 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone]; Ziram inhibits the reaction [HSD11B2 protein results in increased oxidation of Hydrocortisone]; Ziram inhibits the reaction [HSD11B2 protein results in increased reduction of NAD] Dithiothreitol inhibits the reaction [Ziram results in decreased activity of HSD11B2 protein]; Ziram inhibits the reaction [[HSD11B2 protein results in increased oxidation of Corticosterone] which results in increased chemical synthesis of 11-dehydrocorticosterone]; Ziram inhibits the reaction [HSD11B2 protein results in increased oxidation of Corticosterone]; Ziram inhibits the reaction [HSD11B2 protein results in increased reduction of NAD]
Ziram results in decreased activity of HSD17B3 protein Ziram results in decreased expression of HSD17B3 mRNA; Ziram results in decreased expression of HSD17B3 protein
Ziram results in decreased activity of HSD3B1 protein Ziram results in decreased expression of HSD3B1 mRNA; Ziram results in decreased expression of HSD3B1 protein
Ziram inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] Ziram inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]
[2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in increased expression of LEP protein
[2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in decreased expression of LEPR mRNA
Ziram results in decreased expression of LHCGR mRNA; Ziram results in decreased expression of LHCGR protein Ziram affects the expression of LHCGR mRNA; Ziram affects the expression of LHCGR protein
[2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in decreased expression of NMB mRNA
[2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in increased expression of NMBR mRNA
[2-amino-3-chloro-1,4-naphthoquinone co-treated with Ziram co-treated with cyromazine co-treated with 2-methyl-4-chlorophenoxy gamma-butyric acid co-treated with pirimicarb co-treated with Thiram] results in increased expression of NPY1R mRNA
NR1I3 protein affects the susceptibility to [2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with Thiophanate co-treated with thiacloprid co-treated with Ziram]
Ziram results in decreased expression of NR5A1 mRNA; Ziram results in decreased expression of NR5A1 protein Ziram affects the expression of NR5A1 mRNA; Ziram affects the expression of NR5A1 protein
[Ziram co-treated with Thiophanate co-treated with Captan co-treated with Chlorpyrifos co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with thiacloprid] results in increased expression of PDGFRB protein
Ziram results in decreased expression of SCARB1 mRNA; Ziram results in decreased expression of SCARB1 protein Ziram affects the expression of SCARB1 mRNA; Ziram affects the expression of SCARB1 protein
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SERPINE1 mRNA
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SLC16A2 mRNA
Ziram results in decreased expression of STAR mRNA; Ziram results in decreased expression of STAR protein Ziram affects the expression of STAR mRNA; Ziram affects the expression of STAR protein
[Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of SULT1B1 mRNA
[2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of THRSP mRNA; [Dietary Fats co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in decreased expression of THRSP mRNA; Dietary Fats inhibits the reaction [[2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Captan co-treated with Chlorpyrifos co-treated with thiacloprid co-treated with Thiophanate co-treated with Ziram] results in increased expression of THRSP mRNA]
Ziram results in decreased activity of UBA1 protein Trientine inhibits the reaction [Ziram results in decreased activity of and results in decreased ubiquitination of UBA1 protein]; Ziram results in decreased activity of and results in decreased ubiquitination of UBA1 protein